Literature DB >> 27168812

Penehyclidine ameliorates acute lung injury by inhibiting Toll-like receptor 2/4 expression and nuclear factor-κB activation.

N A Wang1, Yue Su1, Xiang-Ming Che1, Hui Zheng2, Zhi-Guo Shi3.   

Abstract

The aim of the present study was to investigate the effect of penehyclidine (PHC) on endotoxin-induced acute lung injury (ALI), as well as to examine the mechanism underlying this effect. A total of 60 rats were randomly divided into five groups, including the control (saline), LPS and three LPS + PHC groups. ALI was induced in the rats by injection of 8 mg lipopolysaccharide (LPS)/kg body weight. The rats were then treated with or without PHC at 0.3, 1 or 3 mg/kg body weight 1 min following LPS injection. After 6 h, serum levels of tumor necrosis factor (TNF)-α and interleukin (IL)-6 were determined by ELISA. In addition, the mRNA expression levels of toll-like receptor (TLR)2 and TLR4 were examined by reverse transcription-quantitative polymerase chain reaction in the lung tissue samples, and nuclear factor (NF)-κB p65 protein expression levels were examined by western blot analysis. The results demonstrated that lung injury was ameliorated by treatment with PHC (1 and 3 mg/kg body weight) as compared with treatment with LPS alone. Injection of LPS significantly increased the mRNA expression levels of TLR2 and TLR4, as well as the protein expression levels of NF-κB p65 in the lung tissue samples. Serum levels of TNF-α and IL-6 were also upregulated by LPS injection. Treatment of the rats with PHC following LPS injection suppressed the LPS-induced increase in TLR2/4 mRNA and NF-κB p65 protein expression levels. PHC also inhibited the increase in TNF-α and IL-6 serum levels. In addition, PHC reduced LPS-induced ALI and decreased the serum levels of TNF-α and IL-6, possibly by downregulating TLR2/4 mRNA expression and inhibiting NF-κB activity, and consequently alleviating the inflammatory response.

Entities:  

Keywords:  endotoxin; inflammatory response; nuclear factor-κB; penehyclidine; toll-like receptor 2/4

Year:  2016        PMID: 27168812      PMCID: PMC4840699          DOI: 10.3892/etm.2016.3154

Source DB:  PubMed          Journal:  Exp Ther Med        ISSN: 1792-0981            Impact factor:   2.447


  35 in total

Review 1.  Toll-like receptor signaling.

Authors:  Shizuo Akira
Journal:  J Biol Chem       Date:  2003-07-30       Impact factor: 5.157

Review 2.  Regulators of endothelial and epithelial barrier integrity and function in acute lung injury.

Authors:  Rudolf Lucas; Alexander D Verin; Stephen M Black; John D Catravas
Journal:  Biochem Pharmacol       Date:  2009-02-03       Impact factor: 5.858

Review 3.  Acute lung injury/acute respiratory distress syndrome (ALI/ARDS): the mechanism, present strategies and future perspectives of therapies.

Authors:  Shi-ping Luh; Chi-huei Chiang
Journal:  J Zhejiang Univ Sci B       Date:  2007-01       Impact factor: 3.066

4.  Upregulation of toll-like receptor 2 gene expression in macrophage response to peptidoglycan and high concentration of lipopolysaccharide is involved in NF-kappa b activation.

Authors:  Y Liu; Y Wang; M Yamakuchi; S Isowaki; E Nagata; Y Kanmura; I Kitajima; I Maruyama
Journal:  Infect Immun       Date:  2001-05       Impact factor: 3.441

5.  NF-kappa B and STAT5 play important roles in the regulation of mouse Toll-like receptor 2 gene expression.

Authors:  T Musikacharoen; T Matsuguchi; T Kikuchi; Y Yoshikai
Journal:  J Immunol       Date:  2001-04-01       Impact factor: 5.422

6.  Signaling by toll-like receptor 2 and 4 agonists results in differential gene expression in murine macrophages.

Authors:  M Hirschfeld; J J Weis; V Toshchakov; C A Salkowski; M J Cody; D C Ward; N Qureshi; S M Michalek; S N Vogel
Journal:  Infect Immun       Date:  2001-03       Impact factor: 3.441

7.  Anisodamine inhibits thromboxane synthesis, granulocyte aggregation, and platelet aggregation. A possible mechanism for its efficacy in bacteremic shock.

Authors:  R J Xiu; D E Hammerschmidt; P A Coppo; H S Jacob
Journal:  JAMA       Date:  1982-03-12       Impact factor: 56.272

Review 8.  Toll-like receptors.

Authors:  Kiyoshi Takeda; Tsuneyasu Kaisho; Shizuo Akira
Journal:  Annu Rev Immunol       Date:  2001-12-19       Impact factor: 28.527

9.  Oxidized phospholipid inhibition of toll-like receptor (TLR) signaling is restricted to TLR2 and TLR4: roles for CD14, LPS-binding protein, and MD2 as targets for specificity of inhibition.

Authors:  Clett Erridge; Simon Kennedy; Corinne M Spickett; David J Webb
Journal:  J Biol Chem       Date:  2008-06-17       Impact factor: 5.157

10.  MD-2, a molecule that confers lipopolysaccharide responsiveness on Toll-like receptor 4.

Authors:  R Shimazu; S Akashi; H Ogata; Y Nagai; K Fukudome; K Miyake; M Kimoto
Journal:  J Exp Med       Date:  1999-06-07       Impact factor: 14.307

View more
  3 in total

1.  Dexmedetomidine mitigates CLP-stimulated acute lung injury via restraining the RAGE pathway.

Authors:  Hongyi Hu; Dongsheng Shi; Chenlu Hu; Xiao Yuan; Juan Zhang; Huaqin Sun
Journal:  Am J Transl Res       Date:  2017-12-15       Impact factor: 4.060

2.  Lats2-Underexpressing Bone Marrow-Derived Mesenchymal Stem Cells Ameliorate LPS-Induced Acute Lung Injury in Mice.

Authors:  Liang Dong; Lang Li
Journal:  Mediators Inflamm       Date:  2019-10-21       Impact factor: 4.711

3.  Systematic identification of the interventional mechanism of Qingfei Xiaoyan Wan (QFXYW) in treatment of the cytokine storm in acute lung injury using transcriptomics-based system pharmacological analyses.

Authors:  Jing-Yi Hou; Jia-Rong Wu; Yi-Bing Chen; Dong Xu; Shu Liu; Dan-Dan Shang; Guan-Wei Fan; Yuan-Lu Cui
Journal:  Pharm Biol       Date:  2022-12       Impact factor: 3.503

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.